XENOPORT INC (XNPT) Upgraded by Zacks to OUTPERFORM

Zacks Zacks Investment Research upgraded shares of XENOPORT INC (XNPT) from NEUTRAL to OUTPERFORM on August 16, 2012, with a target price of $9.30.

XenoPort, Inc. is a biopharmaceutical company focused on developing a portfolio of internally discovered product candidates that utilize the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of existing drugs.

Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.

To get a free copy of the research report on XENOPORT INC (XNPT),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .

Be the first to comment

Leave a Reply